Stephen Rohrer
Primary Care · Wynne, ARNPI 1538611975
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Paratek Pharmaceuticals, Inc. accounts for 74.6% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2022 at $8,358 and has fallen 83.3% since, to $1,397 in 2025. Among primary care clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 198 payments — averaging $73.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$11K
- Organogenesis Inc.$598
- Medtronic$388
- Novo Nordisk$272
- Smith+Nephew$265
- AbbVie$263
- plus $2K from 24 others
What the payments were for
- Consulting fees$7705%
- Speaking & faculty fees$5,82040%
- Travel & lodging$3,65525%
- Food & beverage$4,32430%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 50 | $10,872 |
| Organogenesis Inc. | 9 | $598 |
| Medtronic | 7 | $388 |
| Novo Nordisk | 19 | $272 |
| Smith+Nephew | 13 | $265 |
| AbbVie | 20 | $263 |
| GSK | 9 | $242 |
| Amgen | 7 | $237 |
| AstraZeneca | 7 | $233 |
| Abbott | 3 | $150 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $150 |
| Triad Life Sciences Inc. | 3 | $107 |
| Lilly USA, LLC | 1 | $104 |
| Exact Sciences | 7 | $101 |
| Medline Industries LP | 1 | $97 |
| Boehringer Ingelheim | 4 | $62 |
| Mylan Specialty L.p. | 3 | $51 |
| Sumitomo Pharma America, Inc. | 4 | $51 |
| Reprise Biomedical, Inc. | 3 | $50 |
| Phathom Pharmaceuticals, Inc. | 4 | $46 |
| Sanofi Pasteur Inc. | 2 | $45 |
| Cvrx, Inc. | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Mannkind Corporation | 1 | $25 |
| Lundbeck LLC | 1 | $20 |
| Convatec Inc. | 1 | $16 |
| Nabriva Therapeutics, PLC | 1 | $16 |
| Bioventus LLC | 1 | $15 |
| Pfizer | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUZYRA$10,157
- PuraPly$232
- SIMPLERA SENSOR$196
- FlowMet-R$130
- AIRSUPRA$125
- SIMPLIMAX$123
- Repatha$115
- CARDIOMEMS$106
- MOUNJARO$104
- Puraply Antimicrobial$103
How this compares
$14,580 in reported general payments places this provider in the 95th percentile of 76 primary care providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 92 | $104,977 |
| JardianceEmpagliflozin | 78 | $59,719 |
| OzempicSemaglutide | 53 | $51,324 |
| SantylCollagenase Clostridium Hist. | 40 | $50,830 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $41,111 |
| EliquisApixaban | 31 | $23,589 |
| XareltoRivaroxaban | 21 | $23,057 |
| FarxigaDapagliflozin Propanediol | 30 | $22,334 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $15,311 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $13,033 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $11,546 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $9,720 |
| LinzessLinaclotide | 18 | $9,335 |
| EntrestoSacubitril/Valsartan | 12 | $8,228 |
| Daptomycin | 21 | $6,219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Humulin 70-30 | $104 | $106,242105 claims |
| Boehringer IngelheimJardiance | $62 | $59,71978 claims |
| Novo NordiskOzempic | $272 | $51,32453 claims |
| Smith+NephewSantyl | $265 | $50,83040 claims |
| GSKTrelegy Ellipta | $242 | $41,11148 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $233 | $35,36652 claims |
| PfizerEliquis | $15 | $23,58931 claims |
| AbbVieLinzess | $263 | $9,33518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 76 primary care providers in Arkansas.
Other primary care in Wynne
- Andrew OliverMaumelle$45K
- Chelsea PressonLittle Rock$22K
- Chelsea MarquisSpringdale$12K
- Katherine ThompsonLittle Rock$10K
- Barbara ColeNorth Little Rock$9K
- Celeste WilliamsCenterton$6K
- Jennifer RogersCharleston$4K
- Meghan SkinnerSearcy$4K
- Krystalyn WilliamsLittle Rock$3K
- Sharon ArnoldBatesville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.